Timothy E. Morris Email & Phone Number

Austin, TX, US

Aacolade Pharma LLC is a boutique biotech advisory firm serving clients worldwide. The firm is led by Timothy E. Morris, a retired biotech CFO. Mr. Morris has over 25 years of experience as a public company CFO. He has raised over $2.5 billion and completed over 100 corporate transaction. Mr. Morris and his team of experts provide advisory services.

Aquestive Therapeutics, Inc. (Nasdaq: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standard of care and provide transformative products to improve their lives. They are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of.

Bruxelles, Brussels, BE

Univercells is a global life sciences company with the mission of making biologics accessible to all. Using their combined expertise in scaling, production, and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs. The affiliate companies deploy innovations in infrastructure, drug substance manufacturing.

Châtillon, France, FR

DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates.

Minneapolis, MN, US

Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. The Company was founded in 1988 and is engaged in developing and commercializing products to enhance human health and wellbeing. Humanetics entered the field of radiation modulators in 2003, through a cooperative research program with the.

South Yarra, VIC, AU

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Humanigen is developing lenzilumab as a treatment.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade.

San Carlos, California, US

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a.

San Mateo, California, US

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Mr. Morris was responsible for managing the company's finance operations, corporate development, information systems, commercial strategy, joint steering.

PAION Inc. is a wholly owned subsidiary of PAION AG. PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION’s strategy is to participate in.

Campbell, California, US

Chief Financial Officer, Senior Vice President Global Corporate Development and Finance - VIVUS Inc. (NASDAQ: VVUS) is a biopharmaceutical company focused on the development and commercialization of therapies to treat obesity and restore sexual health. VIVUS’ lead product is Qsymia, a proprietary oral treatment for obesity, was approved in July 2012 and.

Hayward, CA, US

• Member of the Office of the President, Chief Financial Officer and Sr. Vice President Finance, Manufacturing & Administration - Questcor Pharmaceuticals Inc. (AMEX: QSC now NASDAQ: QCOR) is a specialty pharmaceutical.
• Raised $24 million in private equity and debt over three years to finance acquisitions and growth
• Built company to obtain revenues in excess of $16M and EBITDA positive in 3 years
• Sourced, negotiated and closed acquisition of FDA approved product
• Established new disclosure and financial reporting systems to ensure compliance with Sarbanes Act
• Established quality relationships with specialty pharmaceutical/healthcare analysts and bankers

Sydney, NSW, AU

Chief Financial Officer - InterPro was a provider of travel & expense reporting automation services to large corporations worldwide. Its offerings include software, consulting and business process outsourcing services. The Company had over 100 people in two divisions with combined revenue run rate of over $12 million with an annualized operating budget of.

• Vice President Finance & Administration and Chief Financial Officer - RiboGene, Inc. (Amex: RBO) a publicly held biopharmaceutical company merged with Cypros Pharmaceuticals to become Questcor Pharmaceuticals (Amex.
• Completed IPO for RiboGene in May 1998 (AMEX:RBO), One of nine biotech IPO's in 1998
• Raised over $50 million (private $30 million from VC's, public $20 million)
• Second in command behind Chief Executive Officer
• Provide business development, financial and negotiation support for all strategic alliances
• Company spokesman at industry conferences and for analysts, investors and the media

London, GB